| Project/Area Number |
15591075
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
膠原病・アレルギー・感染症内科学
|
|---|
| Research Institution | National Hospital Organization Nagasaki Medical Center, Clinical Research Center |
|---|
Principal Investigator |
NAKAMURA Minoru National Hospital Organization Nagasaki Medical Center, Clinical Research Center, Division of Advanced Medical Research, Director, 長崎医療センター・臨床研究センター, 先端技術研究部長 (40217906)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YATSUHASHI Hiroshi National Hospital Organization Nagasaki Medical Center, Clinical Research Center, Department of Therapeutic Research, 長崎医療センター・臨床研究センター, 治療研究部長 (50360855)
YANO Koji National Hospital Organization Nagasaki Medical Center, Clinical Research Center, Division of International Medical Cooperation, Department of Medical Policy Project, 長崎医療センター・臨床研究センター, 政策医療研究部室長 (60360856)
FUJIOKA Hikaru National Hospital Organization Nagasaki Medical Center, Clinical Research Center, Department of Medical Morphology, 長崎医療センター・臨床研究センター, 形態研究部長 (00264226)
ISHIBASHI Hiromi National Hospital Organization Nagasaki Medical Center, Clinical Research Center, Director General, 長崎医療センター・臨床研究センター, 臨床研究センター長 (80127969)
|
|---|
| Project Period (FY) |
2003 – 2004
|
| Project Status |
Completed (Fiscal Year 2004)
|
| Budget Amount *help |
¥3,500,000 (Direct Cost: ¥3,500,000)
Fiscal Year 2004: ¥1,300,000 (Direct Cost: ¥1,300,000)
Fiscal Year 2003: ¥2,200,000 (Direct Cost: ¥2,200,000)
|
|---|
| Keywords | primary biliary cirrhosis / autoimmune hepatitis / chronic hepatitis C / etiology-associated antigen / prognostic marker / anti-gp210 antibody / laser microdissection / gene expression |
|---|
| Research Abstract |
Background & Aims : The presence of antibodies to the 210-kDa glycoprotein of the nuclear pore complex (gp210) is highly indicative of primary biliary cirrhosis(PBC). However, the significance of anti-gp210 antibody titers for monitoring PBC remains unresolved. Methods : We used an ELISA with a gp210 C-terminal peptide as an antigen to assess serum antibody titers in 71 patients with PBC. Results : Patients were classified into 3 groups : Group A in whom anti-gp210 titers were sustained at a high level, Group B in whom anti-gp210 status changed from positive to negative under ursodeoxycholic acid(UDCA) therapy, Group C in whom anti-gp21 0 antibodies were negative at the time of diagnosis. The rate of progression to end-stage hepatic failure was significantly higher in group A (60%) as compared to groups B (0%) and C (4.2%). The sustained antibody response to gp210 was closely associated with the severity of interface hepatitis. The significance of anti-gp210 antibody was confirmed by National Hospital Organization Study Group for Liver Disease in Japan. Conclusion : The serial quantitation of serum anti-gp210-C-terminal peptide antibodies is useful for monitoring the effect of UDCA and for the early identification of patients at high risk for end-stage hepatic failure.
|
